The profiling of axial spondyloarthritis patient candidate to a biologic therapy

Consensus from a Delphi-panel of Italian experts

GISEA Study Group

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The project aimed to collect expert consensus statements for the profiling of patients with axial spondyloarthritis (axSpA) candidate to biologic agents (bDMARDs) treatment, in order to better define the drivers for the best treatment choice. Methods: The 6 more interesting topics about axSpA patient profiling were identified by the project steering committee and a panel of axSpA Italian experts. A systematic literature review (SLR) was performed for each of the selected topics according to the PICO format. Two rounds of a modified Delphi process were conducted. In the 1st round, the steering committee evaluated the results of the SLR in order to formulate statements for each topic. In the 2nd round, the experts panel discussed, rephrased when needed, and voted the level of agreement (on a 5-point Likert-type scale) for each statement. Consensus was defined as ≥66% agreement. Results: The topics selected for the analysis were the differential efficacy of available bDMARDs on enthesitis/dactylitis, uveitis, radiographic progression and cardiovascular involvement, and the clinical response in non radiographic-axSpA and in patients receiving a second-line bDMARD. The Delphi rounds formulated 19 statements, all reaching the defined level of consensus in a second round including 25 rheumatologists highly skilled in the management of axSpA. Conclusion: Identified consensus statements can help clinicians to apply to routine-care settings the results from clinical studies and international recommendations, providing a guide for individualization of treatment strategy in axSpA patients.

Original languageEnglish
JournalAutoimmunity Reviews
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Biological Therapy
Uveitis
Biological Factors
Therapeutics

Keywords

  • Axial spondyloarthritis
  • biologic drugs
  • expert consensus
  • personalised therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{1938e39232874706a1684a69878f33a6,
title = "The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts",
abstract = "Objective: The project aimed to collect expert consensus statements for the profiling of patients with axial spondyloarthritis (axSpA) candidate to biologic agents (bDMARDs) treatment, in order to better define the drivers for the best treatment choice. Methods: The 6 more interesting topics about axSpA patient profiling were identified by the project steering committee and a panel of axSpA Italian experts. A systematic literature review (SLR) was performed for each of the selected topics according to the PICO format. Two rounds of a modified Delphi process were conducted. In the 1st round, the steering committee evaluated the results of the SLR in order to formulate statements for each topic. In the 2nd round, the experts panel discussed, rephrased when needed, and voted the level of agreement (on a 5-point Likert-type scale) for each statement. Consensus was defined as ≥66{\%} agreement. Results: The topics selected for the analysis were the differential efficacy of available bDMARDs on enthesitis/dactylitis, uveitis, radiographic progression and cardiovascular involvement, and the clinical response in non radiographic-axSpA and in patients receiving a second-line bDMARD. The Delphi rounds formulated 19 statements, all reaching the defined level of consensus in a second round including 25 rheumatologists highly skilled in the management of axSpA. Conclusion: Identified consensus statements can help clinicians to apply to routine-care settings the results from clinical studies and international recommendations, providing a guide for individualization of treatment strategy in axSpA patients.",
keywords = "Axial spondyloarthritis, biologic drugs, expert consensus, personalised therapy",
author = "{GISEA Study Group} and Favalli, {Ennio Giulio} and Andrea Becciolini and Roberto Caporali and Monica Todoerti and Florenzo Iannone and Liliana Dinoia and Marco Sebastiani and Amelia Spinella and Elisa Gremese and Francesco Cianci and Fabiola Atzeni and Francesca Bandinelli and Gianfranco Ferraccioli and Giovanni Lapadula",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.autrev.2018.07.002",
language = "English",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",

}

TY - JOUR

T1 - The profiling of axial spondyloarthritis patient candidate to a biologic therapy

T2 - Consensus from a Delphi-panel of Italian experts

AU - GISEA Study Group

AU - Favalli, Ennio Giulio

AU - Becciolini, Andrea

AU - Caporali, Roberto

AU - Todoerti, Monica

AU - Iannone, Florenzo

AU - Dinoia, Liliana

AU - Sebastiani, Marco

AU - Spinella, Amelia

AU - Gremese, Elisa

AU - Cianci, Francesco

AU - Atzeni, Fabiola

AU - Bandinelli, Francesca

AU - Ferraccioli, Gianfranco

AU - Lapadula, Giovanni

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: The project aimed to collect expert consensus statements for the profiling of patients with axial spondyloarthritis (axSpA) candidate to biologic agents (bDMARDs) treatment, in order to better define the drivers for the best treatment choice. Methods: The 6 more interesting topics about axSpA patient profiling were identified by the project steering committee and a panel of axSpA Italian experts. A systematic literature review (SLR) was performed for each of the selected topics according to the PICO format. Two rounds of a modified Delphi process were conducted. In the 1st round, the steering committee evaluated the results of the SLR in order to formulate statements for each topic. In the 2nd round, the experts panel discussed, rephrased when needed, and voted the level of agreement (on a 5-point Likert-type scale) for each statement. Consensus was defined as ≥66% agreement. Results: The topics selected for the analysis were the differential efficacy of available bDMARDs on enthesitis/dactylitis, uveitis, radiographic progression and cardiovascular involvement, and the clinical response in non radiographic-axSpA and in patients receiving a second-line bDMARD. The Delphi rounds formulated 19 statements, all reaching the defined level of consensus in a second round including 25 rheumatologists highly skilled in the management of axSpA. Conclusion: Identified consensus statements can help clinicians to apply to routine-care settings the results from clinical studies and international recommendations, providing a guide for individualization of treatment strategy in axSpA patients.

AB - Objective: The project aimed to collect expert consensus statements for the profiling of patients with axial spondyloarthritis (axSpA) candidate to biologic agents (bDMARDs) treatment, in order to better define the drivers for the best treatment choice. Methods: The 6 more interesting topics about axSpA patient profiling were identified by the project steering committee and a panel of axSpA Italian experts. A systematic literature review (SLR) was performed for each of the selected topics according to the PICO format. Two rounds of a modified Delphi process were conducted. In the 1st round, the steering committee evaluated the results of the SLR in order to formulate statements for each topic. In the 2nd round, the experts panel discussed, rephrased when needed, and voted the level of agreement (on a 5-point Likert-type scale) for each statement. Consensus was defined as ≥66% agreement. Results: The topics selected for the analysis were the differential efficacy of available bDMARDs on enthesitis/dactylitis, uveitis, radiographic progression and cardiovascular involvement, and the clinical response in non radiographic-axSpA and in patients receiving a second-line bDMARD. The Delphi rounds formulated 19 statements, all reaching the defined level of consensus in a second round including 25 rheumatologists highly skilled in the management of axSpA. Conclusion: Identified consensus statements can help clinicians to apply to routine-care settings the results from clinical studies and international recommendations, providing a guide for individualization of treatment strategy in axSpA patients.

KW - Axial spondyloarthritis

KW - biologic drugs

KW - expert consensus

KW - personalised therapy

UR - http://www.scopus.com/inward/record.url?scp=85055755232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055755232&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2018.07.002

DO - 10.1016/j.autrev.2018.07.002

M3 - Article

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

ER -